AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
NCT04096326
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
198
Enrollment
INDUSTRY
Sponsor class
Conditions
Glabellar Lines
Interventions
DRUG:
AGN-151586
DRUG:
Placebo
Sponsor
Allergan